Ahmad Majzoub
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Ahmad Majzoub has a total of 359 co-authors. Here are the top co-authors by number of shared publications:
- Sandro Cassiano Esteves
ANDROFERT Andrology and Human Reproduction Clinic Campinas Brazil
68 shared publications - Ashok Agarwal
Global Andrology Forum, Global Andrology Foundation, Moreland Hills, OH, USA ; Cleveland Clinic, Cleveland, OH, USA
59 shared publications - Mohamed Arafa
Department of Urology, Hamad Medical Corporation, Doha, Qatar
44 shared publications - Haitham Elbardisi
Hamad Medical Corporation
39 shared publications - Chak-Lam Cho
S. H. Ho Urology Centre, Department of Surgery, The Chinese University of Hong Kong, Hong Kong
37 shared publications Ashok Agarwal
Case Western Reserve University, Moreland Hills, OH, United States
35 shared publications
Latest Publications
- Open Access
- 17 September 2026
- Published by Oxford University Press (OUP) in Human Reproduction Open
- Vol. 2026 (4)
The value of sperm DNA fragmentation testing in clinical practice: routine or case-directed?
- 17 September 2026
- Published by Oxford University Press (OUP) in Human Reproduction Open
- Vol. 2026 (4)
Open AccessThe value of sperm DNA fragmentation testing in clinical practice: routine or case-directed?
- Open Access
- 23 April 2026
- Published by Springer Nature in International Journal Of Impotence Research
Health consequences of anabolic steroids: a sexual-medicine perspective
Nonmedical anabolic–androgenic steroid (AAS) use is increasingly encountered in sexual medicine practice, often presenting through sexual symptoms or fertility concerns rather than overt systemic illness. This review summarizes the major health consequences of AAS abuse with emphasis on sexual and reproductive sequelae and provides a pragmatic approach to evaluation and recovery after cessation. AAS exposure commonly suppresses the hypothalamo–pituitary–gonadal axis, leading to hypogonadism and hormonal imbalance that may manifest as reduced libido, erectile dysfunction, gynecomastia, and impaired spermatogenesis ranging from severe oligozoospermia to azoospermia. Recovery after discontinuation is heterogeneous: endocrine parameters frequently normalize earlier than semen parameters, and prolonged/high-dose exposure is associated with delayed or incomplete recovery in a clinically meaningful subset. Beyond sexual and reproductive harm, convergent observational evidence supports increased cardiovascular risk (remodeling, dysfunction, and adverse events), hepatic injury (particularly with 17α-alkylated agents), hematologic/prothrombotic changes, tendon pathology, neuropsychiatric symptoms, and dermatologic complications, with risk shaped by dose, duration, and polypharmacy. In the absence of robust randomized trials, management should prioritize AAS cessation and relapse prevention. Clinicians should actively screen for organ-specific sequelae and individualize follow-up based on symptom burden, hormonal status, fertility goals, and time since last exposure, with selective use of pharmacological induction of recovery when clinically appropriate.
- 23 April 2026
- Published by Springer Nature in International Journal Of Impotence Research
Open AccessHealth consequences of anabolic steroids: a sexual-medicine perspective
Nonmedical anabolic–androgenic steroid (AAS) use is increasingly encountered in sexual medicine practice, often presenting through sexual symptoms or fertility concerns rather than overt systemic illness. This review summarizes the major health consequences of AAS abuse with emphasis on sexual and reproductive sequelae and provides a pragmatic approach to evaluation and recovery after cessation. AAS exposure commonly suppresses the hypothalamo–pituitary–gonadal axis, leading to hypogonadism and hormonal imbalance that may manifest as reduced libido, erectile dysfunction, gynecomastia, and impaired spermatogenesis ranging from severe oligozoospermia to azoospermia. Recovery after discontinuation is heterogeneous: endocrine parameters frequently normalize earlier than semen parameters, and prolonged/high-dose exposure is associated with delayed or incomplete recovery in a clinically meaningful subset. Beyond sexual and reproductive harm, convergent observational evidence supports increased cardiovascular risk (remodeling, dysfunction, and adverse events), hepatic injury (particularly with 17α-alkylated agents), hematologic/prothrombotic changes, tendon pathology, neuropsychiatric symptoms, and dermatologic complications, with risk shaped by dose, duration, and polypharmacy. In the absence of robust randomized trials, management should prioritize AAS cessation and relapse prevention. Clinicians should actively screen for organ-specific sequelae and individualize follow-up based on symptom burden, hormonal status, fertility goals, and time since last exposure, with selective use of pharmacological induction of recovery when clinically appropriate.
- Open Access
- 23 March 2026
- Published by Taylor & Francis in Arab Journal of Urology
- Vol. 24 (4) , 1-8
Arabic translation, cross-cultural adaptation, and psychometric validation of the satisfaction survey for inflatable penile implant: The SSIPI-AR
Erectile dysfunction (ED) is defined as the persistent inability to achieve and/or maintain a penile erection of sufficient rigidity for satisfactory sexual activity for more than 3 months [1]. ED ...
- 23 March 2026
- Published by Taylor & Francis in Arab Journal of Urology
- Vol. 24 (4) , 1-8
Open AccessArabic translation, cross-cultural adaptation, and psychometric validation of the satisfaction survey for inflatable penile implant: The SSIPI-AR
Erectile dysfunction (ED) is defined as the persistent inability to achieve and/or maintain a penile erection of sufficient rigidity for satisfactory sexual activity for more than 3 months [1]. ED ...
- Open Access
- 6 January 2026
- Published by Springer Nature in Current Urology Reports
- Vol. 27 (1) , 5
Cost Considerations in Penile Implantation Revision Surgery from a Global Perspective
Purpose of Review: Penile prosthesis revision surgery represents a critical yet underexplored aspect of men’s health care. While primary penile prosthesis implantation offers a durable solution for erectile dysfunction unresponsive to medical therapy, complications such as infection, mechanical failure, and patient dissatisfaction often necessitate revision procedures. These surgeries are inherently more complex than primary implantations, requiring greater perioperative resources and incurring higher costs. This review synthesizes global evidence on the economic implications of penile prosthesis revision surgery, with a focus on clinical, procedural, and systemic cost drivers. Recent Findings: Evidence from both urologic and analogous surgical fields highlights the heightened resource utilization and complication rates associated with revision procedures, particularly in the presence of infection or corporal fibrosis. Device-related considerations, institutional capacity, and healthcare policy play significant roles in determining cost and accessibility. Variations in insurance coverage and access across health systems further underscore disparities in timely and equitable care. Comparative data also demonstrate that revision surgeries carry greater perioperative complexity and higher healthcare expenditure than primary implantations. Summary: Penile prosthesis revision surgery should be recognized as a distinct and necessary component of sexual medicine services. Risk-adjusted reimbursement models, improved procedural coding, and regionalization of care to high-volume centers are recommended to optimize outcomes and control costs. Addressing disparities in access and ensuring cost-conscious delivery will be essential for advancing equitable and effective care in this field.
- 6 January 2026
- Published by Springer Nature in Current Urology Reports
- Vol. 27 (1) , 5
Open AccessCost Considerations in Penile Implantation Revision Surgery from a Global Perspective
Purpose of Review: Penile prosthesis revision surgery represents a critical yet underexplored aspect of men’s health care. While primary penile prosthesis implantation offers a durable solution for erectile dysfunction unresponsive to medical therapy, complications such as infection, mechanical failure, and patient dissatisfaction often necessitate revision procedures. These surgeries are inherently more complex than primary implantations, requiring greater perioperative resources and incurring higher costs. This review synthesizes global evidence on the economic implications of penile prosthesis revision surgery, with a focus on clinical, procedural, and systemic cost drivers. Recent Findings: Evidence from both urologic and analogous surgical fields highlights the heightened resource utilization and complication rates associated with revision procedures, particularly in the presence of infection or corporal fibrosis. Device-related considerations, institutional capacity, and healthcare policy play significant roles in determining cost and accessibility. Variations in insurance coverage and access across health systems further underscore disparities in timely and equitable care. Comparative data also demonstrate that revision surgeries carry greater perioperative complexity and higher healthcare expenditure than primary implantations. Summary: Penile prosthesis revision surgery should be recognized as a distinct and necessary component of sexual medicine services. Risk-adjusted reimbursement models, improved procedural coding, and regionalization of care to high-volume centers are recommended to optimize outcomes and control costs. Addressing disparities in access and ensuring cost-conscious delivery will be essential for advancing equitable and effective care in this field.
- Open Access
- 23 February 2025
- Published by Taylor & Francis in Arab Journal of Urology
- Vol. 23 (4) , 255-265
Racial differences in male fertility parameters in 2,996 men examined for infertility in a single center
Several studies have demonstrated racial variations in various diagnostic clinical parameters in different fields of medicine including andrology. Yet, clinical andrological diagnostic is following the lower reference values recommended by the World Health Organization irrespective of the racial descent of men. Therefore, this study aimed to investigate racial differences in hormonal and semen parameters including sperm DNA fragmentation (SDF) and seminal oxidative stress in a large group of patients from Sub-Saharan, Caucasian, Central/South Asian, Middle Eastern, North African, and Southeast Asian descent. In a total of 2,996 infertile men, testis volume, sperm concentration, total sperm count, total and progressive motility, normal morphology, sperm vitality, SDF, oxidation-reduction potential (ORP), and standard hormones were determined and compared. Significant racial differences for various parameters including the incidence of normal ranges values in the racial groups were found. The highest mean sperm concentration had men of Central/South Asian descent (median: 38.0 × 106/mL) while Southeast Asian men had the lowest (median: 22.0 × 106/mL; p < 0.0001). The highest total sperm motility (median: 55.0%) was observed in Caucasian, Central/South Asian, and Southeast Asian men, while Sub-Saharan African men had the lowest (median: 45.0%; p < 0.0001). For SDF, Caucasian men had the lowest sperm DNA fragmentation (median: 16.0%) and ORP values (median: 1.3 mV/106 sperm/mL) as compared to Central/South Asian men (median: 28.0%; p = 0.0263) and Southeast Asian men (median: 2.4 mV/106 sperm/mL; p = 0.0045), respectively. Our results show not only significant racial differences for many of the parameters investigated but also for the incidence of normal values. Therefore, it might be prudent to revisit the concept of globally standardized reference values for all men. Yet, as a limitation, the small number (53) of Caucasian men needs to be mentioned. Larger studies that include functional sperm parameters need to be conducted.
- 23 February 2025
- Published by Taylor & Francis in Arab Journal of Urology
- Vol. 23 (4) , 255-265
Open AccessRacial differences in male fertility parameters in 2,996 men examined for infertility in a single center
Several studies have demonstrated racial variations in various diagnostic clinical parameters in different fields of medicine including andrology. Yet, clinical andrological diagnostic is following the lower reference values recommended by the World Health Organization irrespective of the racial descent of men. Therefore, this study aimed to investigate racial differences in hormonal and semen parameters including sperm DNA fragmentation (SDF) and seminal oxidative stress in a large group of patients from Sub-Saharan, Caucasian, Central/South Asian, Middle Eastern, North African, and Southeast Asian descent. In a total of 2,996 infertile men, testis volume, sperm concentration, total sperm count, total and progressive motility, normal morphology, sperm vitality, SDF, oxidation-reduction potential (ORP), and standard hormones were determined and compared. Significant racial differences for various parameters including the incidence of normal ranges values in the racial groups were found. The highest mean sperm concentration had men of Central/South Asian descent (median: 38.0 × 106/mL) while Southeast Asian men had the lowest (median: 22.0 × 106/mL; p < 0.0001). The highest total sperm motility (median: 55.0%) was observed in Caucasian, Central/South Asian, and Southeast Asian men, while Sub-Saharan African men had the lowest (median: 45.0%; p < 0.0001). For SDF, Caucasian men had the lowest sperm DNA fragmentation (median: 16.0%) and ORP values (median: 1.3 mV/106 sperm/mL) as compared to Central/South Asian men (median: 28.0%; p = 0.0263) and Southeast Asian men (median: 2.4 mV/106 sperm/mL; p = 0.0045), respectively. Our results show not only significant racial differences for many of the parameters investigated but also for the incidence of normal values. Therefore, it might be prudent to revisit the concept of globally standardized reference values for all men. Yet, as a limitation, the small number (53) of Caucasian men needs to be mentioned. Larger studies that include functional sperm parameters need to be conducted.
- Open Access
- 11 September 2024
- Published by Taylor & Francis in Arab Journal of Urology
- Vol. 23 (1) , 53-61
Does age matter? Impact of age on testicular function and pregnancy outcomes following microsurgical varicocelectomy in patients with grade 3 varicocele
To evaluate the effects of age on semen and hormonal parameters following microsurgical varicocelectomy among patients with grade 3 varicocele, and to compare fertility outcomes between younger (N = 550) were divided into two groups based on their age at the time of MV: n = 441) and ≥40 years (n = 109). Preoperative semen analysis and hormonal profiles were collected, and follow-up data including pregnancy outcomes were gathered at 3 and 6 months post-surgery. Post-surgery, the younger group showed significant improvements in sperm count and total motility (p < 0.001 for each) as well as progressive motility (p = 0.005), while older men exhibited a significant increase in progressive motility (p = 0.002). For each group, there were no significant changes in hormonal levels post-surgery. Comparative analysis across the two age groups showed no significant differences in the postoperative extent of semen improvements or pregnancy. MV is a viable option for older infertile patients as it is for younger infertile men with grade 3 varicocele, and both groups can achieve similarly high rates of pregnancy outcomes.
- 11 September 2024
- Published by Taylor & Francis in Arab Journal of Urology
- Vol. 23 (1) , 53-61
Open AccessDoes age matter? Impact of age on testicular function and pregnancy outcomes following microsurgical varicocelectomy in patients with grade 3 varicocele
To evaluate the effects of age on semen and hormonal parameters following microsurgical varicocelectomy among patients with grade 3 varicocele, and to compare fertility outcomes between younger (N = 550) were divided into two groups based on their age at the time of MV: n = 441) and ≥40 years (n = 109). Preoperative semen analysis and hormonal profiles were collected, and follow-up data including pregnancy outcomes were gathered at 3 and 6 months post-surgery. Post-surgery, the younger group showed significant improvements in sperm count and total motility (p < 0.001 for each) as well as progressive motility (p = 0.005), while older men exhibited a significant increase in progressive motility (p = 0.002). For each group, there were no significant changes in hormonal levels post-surgery. Comparative analysis across the two age groups showed no significant differences in the postoperative extent of semen improvements or pregnancy. MV is a viable option for older infertile patients as it is for younger infertile men with grade 3 varicocele, and both groups can achieve similarly high rates of pregnancy outcomes.
- Open Access
- 21 August 2024
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 13 (16) , 4939
Non-Obstructive Azoospermia and Intracytoplasmic Sperm Injection: Unveiling the Chances of Success and Possible Consequences for Offspring
Non-obstructive azoospermia (NOA) is found in up to 15% of infertile men. While several causes for NOA have been identified, the exact etiology remains unknown in many patients. Advances in assisted reproductive technology, including intracytoplasmic sperm injection (ICSI) and testicular sperm retrieval, have provided hope for these patients. This review summarizes the chances of success with ICSI for NOA patients and examines preoperative factors and laboratory techniques associated with positive outcomes. Furthermore, we reviewed possible consequences for offspring by the use of ICSI with testicular sperm retrieved from NOA patients and the interventions that could potentially mitigate risks. Testicular sperm retrieved from NOA patients may exhibit increased chromosomal abnormalities, and although lower fertilization and pregnancy rates are reported in NOA patients compared to other forms of infertility, the available evidence does not suggest a significant increase in miscarriage rate, congenital malformation, or developmental delay in their offspring compared to the offspring of patients with less severe forms of infertility or the offspring of fertile men. However, due to limited data, NOA patients should receive specialized reproductive care and personalized management. Counseling of NOA patients is essential before initiating any fertility enhancement treatment not only to mitigate health risks associated with NOA but also to enhance the chances of successful outcomes and minimize possible risks to the offspring.
- 21 August 2024
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 13 (16) , 4939
Open AccessNon-Obstructive Azoospermia and Intracytoplasmic Sperm Injection: Unveiling the Chances of Success and Possible Consequences for Offspring
Non-obstructive azoospermia (NOA) is found in up to 15% of infertile men. While several causes for NOA have been identified, the exact etiology remains unknown in many patients. Advances in assisted reproductive technology, including intracytoplasmic sperm injection (ICSI) and testicular sperm retrieval, have provided hope for these patients. This review summarizes the chances of success with ICSI for NOA patients and examines preoperative factors and laboratory techniques associated with positive outcomes. Furthermore, we reviewed possible consequences for offspring by the use of ICSI with testicular sperm retrieved from NOA patients and the interventions that could potentially mitigate risks. Testicular sperm retrieved from NOA patients may exhibit increased chromosomal abnormalities, and although lower fertilization and pregnancy rates are reported in NOA patients compared to other forms of infertility, the available evidence does not suggest a significant increase in miscarriage rate, congenital malformation, or developmental delay in their offspring compared to the offspring of patients with less severe forms of infertility or the offspring of fertile men. However, due to limited data, NOA patients should receive specialized reproductive care and personalized management. Counseling of NOA patients is essential before initiating any fertility enhancement treatment not only to mitigate health risks associated with NOA but also to enhance the chances of successful outcomes and minimize possible risks to the offspring.
- Open Access
- 23 May 2024
- Published by Frontiers Media SA in Frontiers in Reproductive Health
- Vol. 6, 1403143
COVID-19 and male fertility: short- and long-term impacts of asymptomatic vs. symptomatic infection on male reproductive potential
Background: Studies exploring the effect of COVID-19 on male reproductive system suggest a detrimental association, however with conflicting results. The aim of this study was to assess the association between COVID-19 infection and male reproductive potential including hormone profiles and semen parameters.Methods: This prospective cohort study included 48 patients with confirmed COVID-19 infection. Patients were subdivided into an asymptomatic group (n = 30) and a group with COVID-19 symptoms (n = 18). Serum hormone levels including testosterone, LH, FSH and estradiol were collected during active infection (baseline, time 0), and at 3 and 6 months following COVID-19 infection. Semen samples (basic semen analysis and oxidation reduction potential) were examined at 3 and 6 months following infection. Student and paired-t tests were used to compare continuous variables between the study groups and across the studied time intervals, respectively. Multivariate binary logistic regression analysis was performed to explore predictors for COVID-19 symptoms during active infection.Results: Patients with COVID-19 symptoms were significantly older (p = 0.02) and had significantly lower serum testosterone levels (p = 0.01) and significantly higher LH: testosterone ratio (p = 0.01) than asymptomatic patients. Multivariate analysis revealed older age (OR = 1.18, p = 0.03) and lower serum testosterone level (OR = 0.8, p = 0.03) as independent predictors of symptomatic COVID-19 infection. Significant increase in testosterone (p < 0.001 for both) and decrease in LH (p = 0.02, p = 0.007) and LH: testosterone (p = 0.02, p = 0.005) levels were observed at 3 and 6 months in patients with COVID-19 symptoms. Asymptomatic patients demonstrated significant increase in testosterone (p = 0.02) and decrease in LH: testosterone (p = 0.04) levels only at 3 months following COVID-19 infection. No significant differences were observed between the two study groups with regards to the semen analysis results obtained at 3 or 6 months following COVID-19 infection.Conclusion: Significantly lower testosterone values are associated with worse disease severity among men with COVID-19 infection. This association appears to be temporary as a significant increase in testosterone levels are witnessed as early as 3 months following recovery. No significant detrimental effect for COVID-19 infection on testicular sperm production is found in this patient population.
- 23 May 2024
- Published by Frontiers Media SA in Frontiers in Reproductive Health
- Vol. 6, 1403143
Open AccessCOVID-19 and male fertility: short- and long-term impacts of asymptomatic vs. symptomatic infection on male reproductive potential
Background: Studies exploring the effect of COVID-19 on male reproductive system suggest a detrimental association, however with conflicting results. The aim of this study was to assess the association between COVID-19 infection and male reproductive potential including hormone profiles and semen parameters.Methods: This prospective cohort study included 48 patients with confirmed COVID-19 infection. Patients were subdivided into an asymptomatic group (n = 30) and a group with COVID-19 symptoms (n = 18). Serum hormone levels including testosterone, LH, FSH and estradiol were collected during active infection (baseline, time 0), and at 3 and 6 months following COVID-19 infection. Semen samples (basic semen analysis and oxidation reduction potential) were examined at 3 and 6 months following infection. Student and paired-t tests were used to compare continuous variables between the study groups and across the studied time intervals, respectively. Multivariate binary logistic regression analysis was performed to explore predictors for COVID-19 symptoms during active infection.Results: Patients with COVID-19 symptoms were significantly older (p = 0.02) and had significantly lower serum testosterone levels (p = 0.01) and significantly higher LH: testosterone ratio (p = 0.01) than asymptomatic patients. Multivariate analysis revealed older age (OR = 1.18, p = 0.03) and lower serum testosterone level (OR = 0.8, p = 0.03) as independent predictors of symptomatic COVID-19 infection. Significant increase in testosterone (p < 0.001 for both) and decrease in LH (p = 0.02, p = 0.007) and LH: testosterone (p = 0.02, p = 0.005) levels were observed at 3 and 6 months in patients with COVID-19 symptoms. Asymptomatic patients demonstrated significant increase in testosterone (p = 0.02) and decrease in LH: testosterone (p = 0.04) levels only at 3 months following COVID-19 infection. No significant differences were observed between the two study groups with regards to the semen analysis results obtained at 3 or 6 months following COVID-19 infection.Conclusion: Significantly lower testosterone values are associated with worse disease severity among men with COVID-19 infection. This association appears to be temporary as a significant increase in testosterone levels are witnessed as early as 3 months following recovery. No significant detrimental effect for COVID-19 infection on testicular sperm production is found in this patient population.
- 1 November 2023
- Published by Georg Thieme Verlag KG in Seminars in Reproductive Medicine
- Vol. 41 (06) , 241-257
Unraveling the Impact of Sperm DNA Fragmentation on Reproductive Outcomes
In recent years, there has been a growing interest in identifying subcellular causes of male infertility, and sperm DNA fragmentation (SDF) research has been at the forefront of this focus. DNA damage can occur during spermatogenesis due to faulty chromatin compaction or excessive abortive apoptosis. It can also happen as sperm transit through the genital tract, often induced by oxidative stress. There are several methods for SDF testing, with the sperm chromatin structure assay, terminal deoxynucleotidyl transferase d-UTI nick end labeling (TUNEL) assay, comet assay, and sperm chromatin dispersion test being the most commonly used. Numerous studies strongly support the negative impact of SDF on male fertility potential. DNA damage has been linked to various morphological and functional sperm abnormalities, ultimately affecting natural conception and assisted reproductive technology outcomes. This evidence-based review aims to explore how SDF influences male reproduction and provide insights into available therapeutic options to minimize its detrimental impact.
- 1 November 2023
- Published by Georg Thieme Verlag KG in Seminars in Reproductive Medicine
- Vol. 41 (06) , 241-257
Unraveling the Impact of Sperm DNA Fragmentation on Reproductive Outcomes
In recent years, there has been a growing interest in identifying subcellular causes of male infertility, and sperm DNA fragmentation (SDF) research has been at the forefront of this focus. DNA damage can occur during spermatogenesis due to faulty chromatin compaction or excessive abortive apoptosis. It can also happen as sperm transit through the genital tract, often induced by oxidative stress. There are several methods for SDF testing, with the sperm chromatin structure assay, terminal deoxynucleotidyl transferase d-UTI nick end labeling (TUNEL) assay, comet assay, and sperm chromatin dispersion test being the most commonly used. Numerous studies strongly support the negative impact of SDF on male fertility potential. DNA damage has been linked to various morphological and functional sperm abnormalities, ultimately affecting natural conception and assisted reproductive technology outcomes. This evidence-based review aims to explore how SDF influences male reproduction and provide insights into available therapeutic options to minimize its detrimental impact.